Takeda Pharmaceutical Balance Sheet

Financials in millions JPY. Fiscal year is April - March.

Millions JPY. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec '25 Dec 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021	Mar '20 Mar 31, 2020
Cash & Equivalents	654,937	457,890	533,530	849,695	966,222	637,614
Short-Term Investments	107,004	15,089	20,174	25,305	36,598	15,822
Cash & Short-Term Investments	761,941	472,979	553,704	875,000	1,002,820	653,436
Cash Growth	-15.92%	-14.58%	-36.72%	-12.75%	53.47%	-9.92%
Accounts Receivable	736,464	668,403	649,429	696,644	783,091	757,005
Other Receivables	21,457	29,207	32,264	27,733	29,623	27,916
Total Trade Receivables	757,921	697,610	681,693	724,377	812,714	784,921
Inventory	1,407,192	1,209,869	986,457	853,167	753,881	759,599
Other Current Assets	189,387	178,312	176,103	141,099	143,478	271,476
Total Current Assets	3,116,439	2,558,580	2,397,956	2,593,642	2,712,893	2,469,432
Net Property, Plant & Equipment	2,083,981	1,989,777	1,691,229	1,582,800	1,453,917	1,386,370
Other Intangible Assets	3,515,628	4,274,682	4,269,657	3,818,544	3,909,106	4,171,361
Goodwill	5,753,268	5,410,067	4,790,723	4,407,749	4,033,917	4,012,528
Long-Term Investments	434,168	430,608	378,857	330,133	348,350	369,455
Other Long-Term Assets	505,288	446,079	429,328	445,150	454,110	411,948
Total Assets	15,408,774	15,108,792	13,957,750	13,178,018	12,912,293	12,821,094
Accounts Payable	467,594	547,521	649,233	516,297	343,838	318,816
Accrued Expenses	572,131	524,420	508,360	443,502	471,278	405,245
Short-Term Debt	583,147	367,251	339,600	203,993	22,153	586,817
Other Current Liabilities	987,311	979,261	984,747	981,938	935,907	865,020
Total Current Liabilities	2,610,183	2,418,453	2,481,940	2,145,730	1,773,176	2,175,898
Long-Term Debt	4,270,174	4,476,581	4,042,741	4,141,418	4,613,218	4,506,487
Other Long-Term Liabilities	884,326	777,100	1,078,399	1,207,348	1,348,722	1,411,223
Total Long-Term Liabilities	5,154,500	5,253,684	5,121,138	5,348,764	5,961,940	5,917,710
Total Liabilities	7,764,683	7,672,137	7,603,078	7,494,495	7,735,116	8,093,608
Common Stock	1,694,763	1,676,596	1,676,345	1,676,263	1,668,145	1,668,123
Treasury Stock	-49,124	-61,259	-100,317	-116,007	-59,552	-87,463
Additional Paid-in Capital	1,751,906	1,747,441	1,728,830	1,708,873	1,688,424	1,680,287
Accumulated Other Comprehensive Income	3,152,680	2,509,310	1,508,119	934,173	366,114	92,564
Retained Earnings	1,095,662	1,400,203	1,541,146	1,479,716	1,509,906	1,369,972
Total Common Shareholders' Equity	7,642,943	7,272,364	6,354,122	5,683,019	5,173,037	4,723,483
Minority Interest	1,147	741	549	504	4,140	4,003
Shareholders' Equity	7,644,091	7,274,005	6,354,672	5,683,523	5,177,177	4,727,486
Total Liabilities & Equity	15,408,774	15,108,792	13,957,750	13,178,018	12,912,293	12,821,094
Total Debt	4,853,321	4,843,832	4,382,341	4,345,411	4,635,371	5,093,304
Net Cash (Debt)	-4,091,380	-4,370,853	-3,828,637	-3,470,411	-3,632,551	-4,439,868
Net Cash Per Share	-	-	-1219.41	-1100.20	-1154.26	-1417.40
Book Value	7,642,943	7,272,364	6,354,122	5,683,019	5,173,037	4,723,483
Book Value Per Share	-	-	2023.77	1801.65	1643.76	1507.94
Tangible Book Value	-1,625,953	-2,412,385	-2,706,258	-2,543,274	-2,769,986	-3,460,406
Tangible Book Value Per Share	-	-	-861.94	-806.28	-880.18	-1104.71

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q